Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4067788 | 0.98 | KMT2A (0.68) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| Bicarbonate SCHEMBL15226101 | 0.97 | KMT2A (0.66) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL12508044 | 0.96 | KMT2A (0.64) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL19090237 | 0.95 | KMT2A (0.68) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4072349 | 0.92 | MEN1 (0.72) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1688072 | 0.82 | LMNA (0.60) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL8784618 | 0.81 | SMN1; SMN2 (0.73) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL14501013 | 0.81 | KMT2A (0.58) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL1912299 | 0.80 | NAMPT (0.64) | KMT2AMEN1ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL6385157 | 0.80 | GFER (0.68) | KMT2AMEN1LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1616859-B1 | Substituted cyclohexyl carboxylic acid compounds | SEIKAGAKU KOGYO CO LTD (JP) | 2013-09-04 | — | — | EP | claimed |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-08-08 | — | — | US | disclosed |
| US-8404747-B2 | Compositions and methods for modulating interaction between polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404747-B2 | Compositions and methods for modulating interaction between polypeptides | THE GENERAL HOSPITAL CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | CREDIT SUISSE AG | 2009-09-17 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511133-B2 | Adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233878-A1 | NOVEL ADENOSINE A3 RECEPTOR AGONISTS | ADORA3, ADORA1, ADORA2A | KMT2A 1872/4885MEN1 3593/4885LMNA 3472/4885 |
| US-20050250729-A1 | Novel adenosine A3 receptor agonists | ADORA3, ADORA2A, ADORA1 | KMT2A 3314/4885MEN1 4611/4885LMNA 4090/4885 |
| US-20130203733-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | IAPP, SERPINA6, SERPINA2 | KMT2A 4744/4885MEN1 1736/4885LMNA 1941/4885 |
| US-20140336178-A1 | COMPOSITIONS AND METHODS FOR MODULATING INTERACTION BETWEEN POLYPEPTIDES | IAPP, SERPINA6, SERPINA2 | KMT2A 4744/4885MEN1 1736/4885LMNA 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.